INTERCEPT-Cryoprecipitation
  • Home
  • INTERCEPT Fibrinogen Complex
    • What’s in the Bag?
    • Pathogen Reduction
    • Dosage
  • Unmet Need
    • Clot Generation
    • Faster is Better
  • Onboarding
  • Resources
    • Package Inserts
    • Product Information
    • Coding Information
    • Case Studies
    • News
    • Webinars
  • Contact Us
Select Page
  • Home
  • INTERCEPT Fibrinogen Complex
    • What’s in the Bag?
    • Pathogen Reduction
    • Dosage
  • Unmet Need
    • Clot Generation
    • Faster is Better
  • Onboarding
  • Resources
    • Package Inserts
    • Product Information
    • Coding Information
    • Case Studies
    • News
    • Webinars
  • Contact Us
Cerus Websites
  • Cerus.com
  • INTERCEPT-USA.com
  • HCP.INTERCEPT-USA.com
  • INTERCEPT-Canada.com
  • INTERCEPTBloodSystem.com
  • INTERCEPT-Cryoprecipitation.com
  • Cerus.com

    The corporate website includes broad information about Cerus, resources for investors, and career opportunities.
  • INTERCEPT-USA.com

    For residents of the United States – Blood centers and transfusion services will find topics related to the production of INTERCEPT pathogen reduced platelet and plasma products.
  • HCP.INTERCEPT-USA.com

    For residents of the United States – Hospital blood banks and healthcare practitioners will find content related to clinical topics, implementation, and education for platelet and plasma products.
  • INTERCEPT-Canada.com

    For residents of Canada – Specific information for pathogen reduced platelets and plasma including package inserts.
  • INTERCEPTBloodSystem.com

    Visitors in Europe, the Middle East, Africa, Asia or Latin America will find information about pathogen inactivated platelets and plasma.
  • INTERCEPT-Cryoprecipitation.com

    For residents of the United States – Learn more about the INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Resources

  • Package Inserts
  • Product Information
  • Coding Information
  • Case Studies
  • News
  • Webinars

Implementing the Use of INTERCEPT® Fibrinogen Complex (IFC) in the Pediatric Setting

Download View

INTERCEPT Cryoprecipitated Fibrinogen Complex (IFC) Product Brochure

Download View

Assessing Impact of INTERCEPT Fibrinogen Complex (IFC) on Wastage and Massive Transfusion Protocols (MTPs)

Download View

2022 AABB Abstract Book

Download View

INTERCEPT Fibrinogen Complex Medicare Coding and Payment Guide

Download View

IFC and PRPCR Coding Information

Download View

INTERCEPT Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR) Product Brochure

Download View

Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR) Package Insert

Download View

Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) Package Insert

Download View

Global Headquarters

1220 Concord Avenue
Concord, CA US 94520
+1 925.288.6000

Rx only.
See Package Insert for full prescribing information, including Contraindications, Warnings and Precautions There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to Package Insert.

LinkedIn
  • Cookie Notice
  • Legal
  • Privacy Policy
Copyright (c) 2022 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.3.0
Indications, Contraindications, Warnings and Precautions
INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

INDICATIONS FOR USE

• Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
• Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
• Second-line therapy for von Willebrand disease (vWD).
• Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.